KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) EBT Margin (2016 - 2025)

Historic EBT Margin for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to 24.92%.

  • Emergent BioSolutions' EBT Margin fell 235400.0% to 24.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.42%, marking a year-over-year increase of 318600.0%. This contributed to the annual value of 13.69% for FY2024, which is 559900.0% up from last year.
  • Per Emergent BioSolutions' latest filing, its EBT Margin stood at 24.92% for Q3 2025, which was down 235400.0% from 11.92% recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' EBT Margin registered a high of 48.47% during Q3 2024, and its lowest value of 539.6% during Q2 2024.
  • Over the past 5 years, Emergent BioSolutions' median EBT Margin value was 14.18% (recorded in 2024), while the average stood at 40.78%.
  • Its EBT Margin has fluctuated over the past 5 years, first tumbled by -4655500bps in 2024, then soared by 5276800bps in 2025.
  • Quarter analysis of 5 years shows Emergent BioSolutions' EBT Margin stood at 34.97% in 2021, then tumbled by -153bps to 18.59% in 2022, then decreased by -6bps to 19.7% in 2023, then rose by 28bps to 14.18% in 2024, then surged by 276bps to 24.92% in 2025.
  • Its EBT Margin stands at 24.92% for Q3 2025, versus 11.92% for Q2 2025 and 41.72% for Q1 2025.